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BACKGROUND:  Dry eye disease (DED) is a common, chronic ocular surface disease 
affecting millions of Americans; it can severely diminish quality of life (QOL).  Many 
patient-reported outcomes (PRO) questionnaires have been developed to assess DED, 
but few have established a minimal clinically important difference (MCID) in accordance 
with FDA guidelines.   
OBJECTIVE:  To establish an initial estimation of the MCID of the UNC Dry Eye 
Management Scale (DEMS) and assess patient perceptions of symptom change versus 
score change.   
METHODS:  I recruited 33 patients who had a prior DEMS score from a UNC 
ophthalmology cornea clinic in Chapel Hill, NC for study in the months of May and June 
2014.  I compared patients’ change in the DEMS scores from the most recent prior visit 
to patient-reported assessments of change in symptoms at the time of this study.  Using 
anchor-based methods to determine an MCID, I obtained linear regression coefficients 
from the comparison to be my estimation of the MCID.  I also recorded clinical 
assessments of the patients’ disease severity, and I administered another questionnaire 
to assess patient perceptions of score change as it relates to symptom change. 
RESULTS:  All 33 patients in this first attempt to establish MCID were included in 
analysis (33.3% male, 67.7% female, mean age 60.5 years).  Anchors were correlated 
with DEMS score changes.  The MCID ranged from ½ point using linear regression 
analysis to 1 point using descriptive statistics.  Patients felt that a change of 
approximately 2 points was needed to represent an improvement/worsening of 
symptoms.  The UNC DEMS had modest correlations with clinical tests. 
CONCLUSIONS:  The UNC DEMS is a valid, responsive PRO instrument that can be 
used easily in the clinic to aid in the management of dry eye disease over time.  
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INTRODUCTION 
 Recognition of the value of patient-reported outcomes (PRO) in health care and 
health care research has been growing.  The importance of PROs is reflected in growing 
policy guidance from the Food and Drug Administration (FDA) and provisions in the 
Affordable Care Act (ACA) such as the creation of the Patient-Centered Outcomes 
Research Institute (PCORI).1–4  As a result, the necessity of developing measurable 
PROs for clinical trials and health care has led to increasing numbers of PRO 
instruments over the past decade in many domains.  The field of ophthalmology is no 
exception.  These instruments have particular value in managing non-curative or chronic 
diseases.   
One common, chronic, ocular disease responsible for a large proportion of eye 
clinic visits each year and a substantial burden of disease is dry eye disease (DED).  Dry 
eye disease affects millions of adults over age 50 and is associated with symptoms such 
as pain, burning, grittiness, tearing, and light sensitivity; it can harm patients’ quality of 
life (QOL).5–9  In fact, time trade-off methods of estimating the burden of disease have 
shown that moderate to severe dry eye disease is felt to be as or more burdensome than 
dialysis, severe angina, and hip fractures.10  Unfortunately, many studies have found a 
relatively poor correlation between clinical assessment of disease severity and patient-
reported symptoms.11  This lack of correlation makes patient-reported assessments of 
symptom burden quite important in treating and managing the disease.  Effective 
monitoring of disease severity and the appropriateness of treatments could benefit from 
a measurable patient-reported outcome that can be followed over time.  Therefore, many 
questionnaires that aim to evaluate relevant domains within dry eye disease have been 
developed.  However, the clinical utility of many questionnaires is still uncertain.12 
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BACKGROUND AND SIGNIFICANCE 
 Over twenty dry eye symptom questionnaires are documented in the current 
literature; however, a recent review identified only six capable of assessing quality of 
life.13  Two instruments, the Ocular Surface Disease Index (OSDI) and the Instrument of 
Dry Eye in Everyday Life (IDEEL) have undergone robust validity and reliability studies 
and have been used in clinical trials.14–18  The most recent version of the OSDI is a 12-
item questionnaire assessing three domains: symptom frequency, symptom bother, and 
environmental triggers.14,19  The questionnaire is scored on a scale from 0 to 100 and 
requires the use of an algorithm and scale to determine a patient’s dry eye disease 
severity.  The IDEEL is a 57-item questionnaire developed to assess 3 domains: “dry 
eye symptom-bother, dry eye impact on daily life…and dry eye treatment satisfaction” 
(p.1).16  However, length and/or multi-step interpretation of scores may make both 
instruments challenging for use within the context of a busy eye clinic. 
 Therefore, our colleagues at UNC developed the UNC Dry Eye Management 
Scale (DEMS), which was born out of the need for a valid, reliable, easy-to-administer, 
and easy-to-interpret instrument that can assess both patient-reported symptoms and 
their effects on daily life.  The UNC DEMS is a single-item instrument that asks patients 
to rate their symptoms and those symptoms’ effects on daily life on a scale from 1-10.  
The instrument was created for use in the clinical setting, with emphasis placed on the 
importance of ease of use and quick interpretability.  It was developed in accordance 
with the PROMIS methodology for development of patient-reported outcomes (PRO) 
instruments and, in recent work, the UNC DEMS has been shown to be both valid and 
reliable, strongly correlating to scores generated by the current gold standard measure, 
the OSDI.2 
However, we recognize that the utility of a PRO tool to be used for monitoring 
disease severity and as a guide for treatment regimens depends largely on its ability to 
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detect change over time and the meaning of that change.  Groups like the COnsensus-
based Standards for the selection of health Measurement INstruments (COSMIN) and 
the Food and Drug Administration (FDA) have recognized the importance of developing 
and choosing appropriate PRO tools for research.1,3,20–23  Included in their guidance is 
the necessity for determining the responsiveness of an instrument – its ability to detect 
change over time.  The FDA recommends determining “a score change in a measure, 
experienced by an individual patient over a predetermined time period that has been 
demonstrated in the target population to have a significant treatment benefit,” often 
referred to as the minimal clinically important difference, or MCID.22  As a result, our 
efforts in further validating the UNC DEMS are now focused on the next portion of our 




Patient recruitment and participation 
 Currently, just one ophthalmologist (R.D.) regularly administers the DEMS to dry 
eye patients seen at UNC ophthalmology outpatient clinics.  Consequently,  with the 
guidance of my faculty advisors, I recruited all 33 patients for this study from this one 
provider during the months of May 2014 and June 2014.  To be included in the study, 
patients must be 18 years of age or older, have a diagnosis dry eye disease (ICD-9 
375.15 - tear film insufficiency), and have at least one previously documented DEMS 
score.  I wanted to evaluate the responsiveness of the DEMS over time; therefore, I did 
not exclude patients based on etiology of DED.  Because the DEMS has only been 
validated in English, I recruited only English-speaking patients for the study.  After 
receiving UNC IRB approval of the study, I began to identify eligible participants at 
regularly scheduled clinic appointments.  I then obtained consent from the patients who 
agreed to participate in the study.  I collected age and sex data along with date and 
score of the most recently recorded DEMS score.  If available, I also recorded prior 
clinical assessments of dry eye disease including Schirmer tear production test, tear 
break-up time (TBUT) and Oxford grading scheme for dry eye score from the 
corresponding visit.   
Patients underwent their usual clinical assessment and care during their visit for 
dry eye disease, including administration of the UNC DEMS during initial work-up by the 
technician prior to evaluation by physician and/or researcher.  If the UNC DEMS had not 
been administered prior to the patient being approached for participation in the study, 
student researchers would first administer the DEMS before continuing with the study 
data collection.  Those administering the UNC DEMS were instructed to do so using the 
following statement: “Using the examples below (pointing to UNC DEMS scale), please 
circle the one number that best describes your dry eye symptoms and how they affect 
 5 
your daily life over the past week.”  The UNC DEMS was then scanned into the medical 
record and the score is recorded within the patient’s medical record for that visit.  The 
UNC DEMS questionnaire can be found in Appendix B. 
Clinicians, or researchers with clinician supervision and confirmation, also 
conducted routine assessments for tear production and tear film quality, as well as an 
evaluation of the ocular surface.  Evaluations were made via Schirmer test, evaluation of 
tear breakup time, and ocular surface evaluation via fluorescein staining using the 
Oxford grading scheme for dry eye respectively.  Patients’ participation in the study did 
not influence the clinical or therapeutic course of disease management.  To compensate 
participants for their time, we offered to enroll them in a lottery for a $10 gift card at the 
conclusion of the study.  We determined winners by random number generator using de-
identified patient information, and gift cards were mailed to those selected from the 
lottery. 
 
Dry Eye Symptom Change Questionnaire 
 Based on prior research and literature on acceptable methods for determining 
the responsiveness of patient-reported questionnaires, and with the guidance of my 
faculty advisors, I  developed a single-item, Likert scale questionnaire to serve as an 
anchor for within-patient global transition assessment, or what we call the global change 
assessment (GCA).22,24–26  The questionnaire, called the Dry Eye Symptom Change 
Questionnaire (DESCQ), asks patients, “compared to your last visit, how are your dry 
eye symptoms now?”  Patients responded by choosing one of the following global 
transitional assessments: “much worse, somewhat worse, a little worse, the same, a little 
better, somewhat better, or much better.”  The DESCQ also includes questions about 
patients’ perceptions of symptom change and their current therapeutic and/or behavioral 
methods for managing their disease.   
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To serve as an additional reference for measuring patients’ beliefs on symptom 
change as it relates to their DEMS score, we also asked patients the following questions:  
 
“How many points would your score have to change to show that you felt like your 
symptoms were getting better?  That is, how much change would be a meaningful 
improvement in quality of life for you?” 
 
“How many points would your score have to change to show that you felt like your 
symptoms were getting worse?  That is, how much change would mean that your 
symptoms were making your quality of life worse?”  
 
“If you could choose a number on the UNC DEMS that would be your goal score 
for treatment of your dry eyes – the place you’d like to get to – what would that 
number be?“ 
 
The questionnaire in its final administered version can be found in Appendix B.   
 
Statistical Analysis 
 To be included in the analysis, participants must have had a previously recorded 
DEMS score and must have met all other inclusion criteria.  Because I asked patients to 
consider their symptoms and how they have changed since last visit, I recorded only the 
most recent score for those patients with multiple prior DEMS scores.  For those 
reporting a range of numbers (e.g. “1 to 2 points”) rather than a single score for either 
their prior DEMS, current DEMS, or any other question, I used the average of the range 
reported for the statistical analysis.  For example, if a patient reported “1 to 2 points,” I 
used “1.5” as the value for data analysis. I initially scoured the data for missing values, 
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which I replaced with last known value carried forward.  If no known previous values 
were available, the missing entry was omitted from the analysis. 
 I compared the prior DEMS score to the current DEMS score and determined the 
difference in scores.  Scores representing less severe disease are represented by lower 
numbers on the UNC DEMS with 1 being the lowest severity and 10 the highest.  I chose 
to calculate the difference by subtracting the previous DEMS score from the current 
DEMS score.  Therefore, a negative change represented a patient-reported 
improvement and vice versa.  This scoring choice dictated that I would base the DESCQ 
on a Likert scale centered at numerical “0” to serve as anchors for patient-reported 
global change assessments (GCA).  The responses “much worse, somewhat worse, a 
little worse, the same, a little better, somewhat better, and much better” corresponded to 
an assigned numerical value of “-3, -2,-1, 0, 1, 2, or 3” respectively.  As such, a 
relationship could be assessed between patient-reported symptom change (GCA) over 
time and the actual change in DEMS score. 
 I recorded clinical evaluations of disease severity using Schirmer test, TBUT, and 
Oxford grading scheme for each eye individually and then averaged scores for each eye 
to enter into the statistical analysis as a single variable for each test.  Rather than 
convert test values into arbitrary categories of normal or gradations of severity, my 
advisors and I decided to treat each test as a continuous variable for correlation 
analysis.   
 This study’s primary outcomes were the change in DEMS score and the patient-
reported GCA.  Secondary outcome relationships included the association of scores with 
age, sex, number of days since last visit, DEMS score at last visit, Schirmer test, TBUT, 
Oxford score, patient responses to perceptions of smallest incremental 
improvement/worsening in DEMS score, and goal DEMS score.   
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Because patients seen in the clinic are undergoing treatment for their dry eye 
disease, we expected most to report improvement over time or at least no worsening.  
Therefore, to account for the likely small sample sizes within the “worsening” GCA 
categories, I folded data for statistical comparisons across GCAs by using the magnitude 
of change for each incremental category regardless of the direction.  In this manner, 
data for “a little worse” were paired with “a little better,” “somewhat worse” was paired 
with “somewhat better,” and “much worse” paired with “much better” to create 3 
categories of incremental change.  All other analysis, including estimation of the MCID, 
was done using unfolded data. 
 
Estimation of the MCID.  Developers of the OSDI and the IDEEL have 
employed collapsing of subgroups and folding of data to account for small sample sizes 
within groups to improve their statistical power during analysis.15,17  Using a method 
similarly reported by Miller and colleagues, I used linear regression modeling to establish 
our estimation of the MCID.15  Although the authors used folded data for their linear 
regression modeling, I opted to not fold the data for this modeling.  Linear regression 
analysis allows us to use the entire spectrum of change in patient-reported global 
change assessments regardless of direction and magnitude, thereby eliminating concern 
about small sample size within subgroups.  In this way, my estimation of the MCID 
represents the predicted change in DEMS score as a function of the patient’s rating of 
symptom change.   
I initially examined the data for correlation between actual changes in DEMS 
score and reported global change assessments using Spearman’s rank correlations to 
assess the legitimacy of the anchors in the data analysis.  I also examined correlations 
between all other independent variables to ascertain whether the independent variables 
are collinear prior to assessing their weight in estimating the MCID.  After bivariate 
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analysis to characterize the unadjusted associations between the study variables of 
interest (age, sex, days since last visit, and previous DEMS score) and the change in 
DEMS score since the last visit, I examined their independent association using a 
multiple linear regression model.  I first conducted a multiple linear regression analysis 
including all independent variables regardless of significance.  Then, in a step-wise 
fashion, I dropped those variables without a statistically (α = 0.05) or clinically significant 
(>10% change) relationship to the change in DEMS score.  I used the final, reduced 
model including the most significant variables for estimation of the MCID using 
coefficients from the linear regression fit to the data.   
 
 Correlation of DEMS with clinical findings.  The likelihood of non-normal 
distribution of data based on DEMS scores and patient-reported GCA directed me to use 
Spearman’s rank correlations to assess the relationship between patient-reported 
disease severity via DEMS score and clinical assessments of disease severity via 







This analysis results from exploring the data produced by a total of 33 
participants.  The majority of participants were women (67.7%) and the average age of 
all participants was 60.5 years.  On average, patients went 122.5 days between visits 
and had an average prior DEMS score of 5.33 (Table 1).  All data were available for 30 
of the 33 patients (90.9%).  Those who were missing data did not have last values to 
carry forward and were missing either all three clinical assessment tests (1 patient) or 
deferred the Schirmer test (2 patients).  No patients were missing DEMS scores and all 
fully completed the DESCQ. 
The vast majority of patients reported that they felt their symptoms were the 
same or better, with only 4 patients reporting a worsening of symptoms since their last 
visit, and none said “much worse” (Figure 1).  Correlations of DEMS score change with 
the GCA showed a moderate, statistically significant correlation, validating the use of our 
anchors for this study (Table 2).  I also found that compared to other independent 
variables, the DEMS score change was statistically significantly correlated with the 
number of days since the last visit as well as the last DEMS score.  Age and sex were 
not correlated with the change in DEMS score.   
Table 3 shows the average score change using folded data comparing patient-
reported global change assessments.  Literature has described using the mean score 
change for the smallest GCA anchor as an arbitrary method for determining the MCID.24–
26  The average change for those rating their symptom change to be “a little 
better/worse” was 1.09 (n = 11).  By this method, the MCID would be approximately 1 
point on the DEMS scale.  For the next incremental change rating of “somewhat 
better/worse,” the mean score change was 1.81 (n = 8), which shows an expected 
increase in magnitude in score change of almost 1 point paired with a greater 
improvement/worsening of symptoms.  However, the largest change in symptom 
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category “much better/worse” had a mean change in score of only 1.00 (n = 6)  Although 
the trends in score change appear to be consistent with an expected increase in 
magnitude of change with each incremental rating of symptom change, the smaller 
sample size for this category likely limits the certainty of our findings.  
 
Patient perceptions of symptom and score change – responses to DESCQ  
When I interviewed patients using the DESCQ, I also wanted to explore patient 
perceptions of how a meaningful change in symptoms would be represented in the score 
change on the DEMS.  The frequency of patients’ estimations of a meaningful score 
change is reported in Figure 1.  Interestingly, patients reported that their DEMS score 
would have to improve by 2.0 points on average to show that their symptoms were 
getting better (Table 4).  Conversely, patients reported that on average a 2.3 point score 
change in the opposite direction would show that their symptoms were getting worse.  
When I asked what their goal score for treatment would be, the vast majority of patients 
reported wanting to get to the lowest score possible of 1 point (Figure 2).  The average 
goal score was 1.4.  No patients reported a current DEMS score of 1. 
The relationship between the independent variables and the change in DEMS 
score over time shows that longer time between visits was correlated with worsening 
DEMS scores since last visit.  Linear regression results produce a statistically significant 
trend of an estimated worsening of 1.3 points for every 100 days since the last visit (p = 
0.003) (Figure 3).  In this sample of patients, the average time since last visit was 122.5 
days.  When I dichotomized by time since last visit to this mean, dividing patients into 
those who had gone 120 days since last visit (N=14) and those who waited less than 
120 days between visits (N=19), patients with less time between visits had an average 
score change of -1.45 points, while those waiting longer had an average score change of 
+0.17 (Table 5).  Paired t-test revealed that this was a statistically significant difference 
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of means (p = 0.006).   However, those who had 120 days since the last visit also 
tended to have higher DEMS scores at their last visit (Table 6).  The relationship 
between the worsening in DEMS score and length of time between visits maybe be 
partially explained by the higher scores at the last visit, but this does not explain why 
those with worse DEMS scores would wait longer before returning to their 
ophthalmologist.  Linear regression analysis of the DEMS score change and the last 
DEMS score also shows that those with higher DEMS scores at their previous visit 
tended to show greater improvements (Figure 4).  Clinically, those with better managed 
symptoms and, thus lower DEMS scores, tend to follow up less frequently, which would 
be consistent with smaller improvements that are closer to goal scores over longer 
periods of time. 
As literature has often shown that clinical assessments of dry eye disease can be 
poorly correlated with patient-reported symptoms, I also wanted to evaluate the 
correlation of clinical signs of disease with what patients reported via their DEMS 
scores.11  I was able to achieve statistically significant correlations between the DEMS 
scores and all three clinical tests (Table 7).  Though not strongly correlated, the results 
of each test were moderately associated with DEMS scores when treated as continuous 
variables ranging from -0.3559 for TBUT to -0.4045 for Schirmer test.    Higher Schirmer 
score represent increasing amounts of tear production and longer TBUT suggests 
healthier tear films.  Conversely, higher Oxford scores indicate higher amounts of 
fluorescein staining, which indicates more severe dry eye disease.  Therefore, the 
direction of correlation for each test with the DEMS is what we would expect to see, and 
the findings further validate the utility of the DEMS as a meaningful health outcome. 
Figure 5 is a plot of actual DEMS score change against how patients reported 
their symptoms had changed since their last visit.  An unadjusted linear regression 
model yielded a statistically significant relationship (R-squared 0.18, p = 0.014) with a 
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beta coefficient of -0.54 (CI -0.97, -0.12), which represents our estimation of the MCID.  
As our earlier data analysis had shown, the DEMS score change may also be a function 
of both the length of time since the last visit as well as the score at the last visit.  
Therefore, we ran a linear regression analysis adjusted for both days since last visit and 
the previous DEMS score.  The adjusted regression yielded similar values and a 
stronger strength of association (beta = -0.56; CI -0.99, -0.13; R-squared 0.43; p = 
0.013).  Based upon our linear regression analysis, we estimate that the MCID for the 
UNC DEMS is approximately one half  (½) a point on a 10 point scale, making the UNC 
DEMS capable of giving both patients and clinicians a fine-grained indication of 
improving or worsening disease.  
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DISCUSSION 
The oft-described lack of correlation between clinical signs and patient-reported 
severity of symptoms in dry eye disease makes managing the disease difficult.11  That 
dry eye disease cannot be cured further contributes to the challenge, which then 
requires that physicians and patients alike be engaged in a long-term process of disease 
management.  Without a meaningful health outcome measurement to guide the 
treatment course physicians may face additional obstacles and uncertainty of treatment 
effectiveness and/or appropriateness.  Therefore, many dry eye PRO instruments have 
been developed to address such challenges.13  However, the responsiveness, or ability 
to detect a change over time, and the minimal clinically important difference of a change 
in PRO measure for the vast majority of these instruments has not been evaluated.  The 
FDA has recognized the importance of developing PRO instruments for both clinical 
trials research and drug label claims, and has established guidelines for PRO instrument 
development, including the establishment of an MCID.3,22,23  Furthermore, the 
International Dry Eye WorkShop (DEWS), a well-recognized group that produces timely 
publications with summaries of extensive data and literature analysis within the field of 
dry eye, argues that “clinically meaningful changes in questionnaire scores need to be 
defined “(p. 105)27  In accordance with such guidelines, we have taken on the challenge 
and responsibility of developing and validating the UNC DEMS and, now, its MCID. 
My faculty advisors, my fellow investigators, and I not only wanted establish an 
MCID using acceptable methods described in literature, but we also wanted to assess 
patient perceptions about the magnitude of meaningful score changes as well as a goal 
score for treatment on the UNC DEMS.  We chose an anchor-based method using 
within-patient global transitions assessment, or what we called the GCA.  We then 
compared the patient-reported magnitude and direction of symptom change since the 
last visit and compared that to the actual changes in DEMS score.  Using a method 
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similar to that employed by the developers of the MCID for the OSDI, I chose to use the 
coefficients from a linear regression analysis to estimate the MCID.  I also looked at the 
average score change for those reporting the smallest incremental change in symptoms 
from last visit, as well as what patients say is the change in DEMS score that would 
mean an improvement/worsening of symptoms to them.  Based on my linear regression 
results, I estimated that the MCID of the UNC DEMS is about half a point.  However, I 
also recognize that the average score change for those reporting “a little better/worse” 
was approximately 1 point, and patients themselves said that an average of 2 points was 
necessary to reflect an improvement or worsening of symptoms.   
Several factors may contribute to our findings.  First and foremost is the small 
overall sample size, and even smaller sizes for between group comparisons.  We feel 
that using all 33 data points within a linear regression model gives us better statistical 
confidence in our findings, whereas group-by-group mean comparisons with small 
sample sizes and wide standard deviations limit the certainty of the results of those 
tests.   
Second, another limitation to using within-patient global transition assessments 
as anchors for establishing an MCID is that it relies on the patient’s ability to recall the 
time period between the current visit and the most recent prior visit with some subtlety.  
For example, some patients may have considered their symptoms at the beginning of 
their treatment course and report feeling “much better” since that time rather than the 
time of their last visit, which may have only been incrementally better.  This may explain 
why some patients said they were feeling “much better” yet had small or no improvement 
in their scores.  This challenge is inherent to using within-patient global transition 
assessments for anchor-based determination of MCID, and is not unique to our study.   
A third caveat to our estimation of the MCID is that it relies on the proper 
administration of the DEMS.  During the study, I found in a few cases that technicians 
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trained to properly administer the DEMS had not done so according to our instructions.  
Although the UNC DEMS is a scale from 1-10, it is not equivalent to an arbitrary 
symptom severity rating from 1-10.  Rather, the numerical choices are anchored by 
examples provided on the scale and it has been validated only as an administered 
questionnaire. 
Fourth, by using a linear regression analysis to estimate our MCID, I then 
assume that each incremental change is perceived to be equivalent anywhere along the 
scale.  For example, a 1-point change from 9 to 8 would be equivalent in the perceived 
change in symptoms as a change in score from 3 to 2.  Subsequently, the analysis also 
assumes that the MCID is the same for movements in score in either direction on the 
scale.   As such, we assume that a ½ point worsening is equivalent to a ½ point 
improvement, in terms of patient perceptions of symptom change. Further testing should 
help unravel these questions of directionality and floor and ceiling effects.   
Additional considerations may contribute to the results of this study.  On the 
DESCQ, patients were not specifically asked about what the smallest change in DEMS 
score would be to reflect the smallest meaningful or noticeable change in symptoms.  
Although we would expect the answer to this question to be less than the mean of 2 
points that we discovered, we also feel that asking in this manner would be slightly 
leading.  Our questions allowed patients to answer in an unbiased fashion and may in 
fact represent true patient perceptions.  However, there is a possibility that some 
patients had difficulty understanding the meaning of the question and may have been 
providing responses relative to their actual DEMS score, which would bias our results 
towards a larger mean change.  A few patients did require clarification questions and 
there is no way to know that patients accurately understood how to answer the 
questions.  Despite these uncertainties we feel that the vast majority of patients 
 17 
answered the questions with an appropriate understanding and the questions did 
capture what patients believed to be meaningful changes in score. 
We also did not consider the length of time patients have been coping with their 
dry eye disease, which may also have some relationship to the magnitude of change 
from visit to visit.  Those with the disease for longer lengths of time may have reached 
what they have come to accept as reasonable  DEMS scores and may be less likely to 
change from visit to visit.  We may be able to infer this from our data showing that 
patients with higher DEMS scores were also more likely to have bigger improvements in 
their score.  Other limitations include not blinding researchers assessing clinical severity 
of disease to prior/current DEMS scores.   
One particular finding that may not be surprising, but may provide some useful 
evidence for frequency of visits for managing dry eye disease, is that those who had 
gone longer between visits were more likely to report either no change or a worsening of 
their symptoms according to DEMS scores (Table 5 & Figure 3).  Although there is no 
standard guideline for frequency of visits for managing dry eye, clinicians tend to space 
visits out when a desired level of symptom control has been reached.  According to our 
data, however, waiting for longer periods of time between visits may increase the 
likelihood of worsening of symptoms.  But because the DEMS ask patients to consider 
their symptoms over the past week, a large variation in symptoms over time may make 
this association difficult to establish.  Another study is required to determine how the 
length of time between visits actually affects disease management and patient-reported 
symptom burden. 
Although this study has some minor, yet significant, limitations, it is certainly not 
without strengths.  By using patients seen by the same provider, I can be more certain 
that clinical assessments of dry eye disease were more equal, valid and reliable from 
patient to patient and may be why we were able to obtain modest correlations between 
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signs and symptoms.  By recruiting patients at their normally scheduled appointments, I 
also had the advantage of having different follow-up times between visits.  This allowed 
me to see the responsiveness of the DEMS over different lengths of time and within the 
natural clinical setting and disease course.   
I am also confident that in this small feasibility study for establishing the MCID we 
were able to demonstrate that the UNC DEMS is in fact a responsive PRO instrument 
that can be used to aid physicians’ therapeutic strategies for dry eye disease over time.  
Modest, statistically significant correlations with clinical tests of disease severity also 
demonstrate further validity of the UNC DEMS as a meaningful health outcome 
measure.  Another, larger study will validate my estimation of the MCID and may provide 
further insight into how to better manage patients with dry eye disease.  Although I 
conducted this study with only English speaking patients, a colleague is also currently 
developing and validating a Spanish version of the UNC DEMS.  Future research will 
involve validity and outcomes studies across multiple providers and centers for both 
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Table 1. Participant characteristics 
Characteristic 
 All participants 
(N = 33) 
Sex, No. (%) 
     Male 




Age, mean (SD, range)  60.5 (13.9, 32-83) 
Days since last DEMS, mean (SD, range) 122.5 (67.0, 25-244) 
Most Recent DEMS, mean (SD, range) 5.33 (1.97, 2-9) 
SOURCE:  data collected by first author for the UNC DEMS MCID study. 
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Table 2. Correlation of the DEMS score change with independent variables 
Variable 
Correlation with DEMS score 
change 
Global Change Assessment -0.4229   (p = 0.014) 
Age -0.1042   (p = 0.564) 
Sex +0.3081   (p = 0.081) 
Days since last DEMS +0.5069   (p = 0.003) 
Last DEMS score -0.3741   (p = 0.032) 




Table 3. DEMS score change by patient-reported Global Change Assessment 
Change category N of cases Mean change, DEMS score 
(SD) 
The Same 8 +0.44 (1.05) 
A little better/worse 11 -1.09 (1.32) 
Somewhat better/worse 8 -1.81 (1.58) 
Much better/worse 6 -1.00 (2.37) 




Table 4. Participant perceptions of DEMS changes 
Category Mean (SD, range) 
Smallest Improvement 2.0 (0.95, 1-4.5) 
Smallest Worsening 2.3 (1.27, 1-4.5) 
Goal Score 1.4 (0.77, 1-3) 




Table 5. Mean DEMS score change by days since last visit 
Group No. Mean (SD, CI) 
≥120 Days 14 0.17 (1.49; -0.681, 1.04) 
<120 Days 19 -1.45 (1.64, -2.24, -0.657) 
  p = 0.006 









Table 6. Mean DEMS score at last visit 
Group No. Mean (SD, CI) 
≥120 Days 14 4.4 (2.03; 3.26, 5.60) 
<120 Days 19 6.0 (1.68, 5.19, 6.81) 
  p = 0.021 




Table 7. Correlation between DEMS score and clinical assessment of disease severity 
(Spearman’s Rank Correlation for non-normal distribution) 
Clinical Test 
Correlation with Current 
DEMS  
Schirmer Tear Production Test -0.4045   (p = 0.0266) 
Oxford Grading Scheme +0.3713   (p = 0.0364) 
Tear Break-up Time -0.3559  (p = 0.0456) 
SOURCE:  data collected by first author for the UNC DEMS MCID study. 
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FIGURES 
Figure 1. Frequency plot of Global Change Assessment responses
 




























Global Change Assessment 
Frequency of Responses by Global Change 
Assessment 
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Figure 2. Frequency of responses to DESCQ 
 




























Figure 3. Plot of change in DEMS score vs. days since last visit
 
SOURCE:  data collected by first author for the UNC DEMS MCID study. 
 
 
y = 0.0133x - 2.3837 






















Days Since Last Visit 
DEMS Score Change vs Days Since Last Visit 
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Figure 4. Plot of change in DEMS score vs. last DEMS score
 SOURCE:  data collected by first author for the UNC DEMS MCID study. 
  
y = -0.3331x + 1.019 






















DEMS Score at Prior Visit 
DEMS Score Change vs Last DEMS Score 
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Figure 5. DEMS score change vs. Global Change Assessment
 























Global Change Assessment 
DEMS Score Change vs  
Global Change Assessment 
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APPENDIX A: Systematic Review 
Establishing the Minimal Clinically Important Difference in Patient Reported Dry Eye 
Questionnaires: A Systematic Review of Methods 
 
INTRODUCTION 
 The International Dry Eye WorkShop (DEWS) defines dry eye disease (DED) as 
“a multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the 
ocular surface.”1  Symptoms often include, but are not limited to, ocular pain, burning, 
tearfulness, grittiness, and photophobia.2  DED affects about 1.68 million men and 3.23 
million women older than age 50.3,4  Although DED is more prevalent in older 
populations, DED can occur in younger patients and has an estimated 5% to 30% of the 
population at various ages in the United States.5  Risk factors associated with DED 
include increasing age, female sex, hormonal changes, systemic autoimmune disease, 
diabetes mellitus and eye-related pathology.6  Research has demonstrated that DED 
diminishes an individual’s quality of life (QOL), hindering the ability to carry out daily 
activities such as reading, computer use and work-related tasks, leading to significant 
lost productivity each year.6  Importantly, research has shown that QOL decreases as 
DED severity increases.7  Utility assessments using time trade-off (TTO) methods have 
found that moderate to severe dry eye scores very similarly to other chronic conditions 
such as dialysis, severe angina and hip fractures.8   
Further complicating the burden of disease is the lack of correlation between the 
severity of clinical findings with the symptoms described by patients with DED.  Current 
clinical assessments of dry eye include tests of tear production and determination of 
ocular surface damage, however neither are reliable indicators of the severity of 
symptoms, leading to reliance on symptom-based diagnoses of DED.9  DED is a chronic 
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condition that is currently without a cure.  Therefore, therapies for DED are palliative 
rather than curative and revolve around improving tear production or decreasing 
evaporative loss of tears, which can be achieved through use of pharmacologic agents 
and/or lifestyle modifications.10  However, the lack of correlation between clinical signs 
and symptoms of the disease makes assessment of treatment effectiveness difficult, 
which places great importance in the use of valid and reliable patient-reported outcomes 
(PRO) instruments for managing dry eye disease. 
 
Evaluating PROMs 
Recognition of the importance of PRO measures has increased considerably 
over the past two decades and has led to the emergence of numerous patient-reported 
outcome measures (PROMs).  PROMs intended to measure quality of life have garnered 
particular attention, especially for use within research and clinical trials.  As a result, 
several groups have developed criteria for evaluating PRO instruments.  The Scientific 
Advisory Committee (SAC) of the Medical Outcomes Trust was commissioned to 
develop a set of attributes and review criteria for evaluating instruments used in 
measuring quality of life.11  The COSMIN checklist has been well regarded as the 
standard for appraising psychometric properties of PROMs and includes the following 
measures: internal consistency, reliability, measurement error, content validity, structural 
validity, hypothesis testing, cross-cultural validity, criterion validity, responsiveness, and 
interpretability.12  Since PROMs are now more widely used in clinical trials for support of 
drug labeling claims, the Food and Drug Administration has also provided guidance for 
use of PROMs and criteria for their evaluation.13   
However, the utility of the PROMs goes beyond its psychometric properties and 
attributes, especially in the clinical setting where interpretability of these measures is 
influential in managing patient symptoms and therapies as in dry eye disease.  The FDA 
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created the Study Endpoints and Label Development (SEALD) group to help with 
interpreting results of PROMs.  Although their guidance is aimed toward the use of 
PROMs in research, the use of PROMs in the clinical setting can also benefit from 
established criteria for interpretability.  The SEALD group has recommended 
establishing what is called the “minimal clinically important difference” (MCID) also 
referred to as the “minimal important difference” (MID), “minimally important change” 
(MIC) and other labels.  The MCID in essence reflects “a score change in a measure, 
experienced by an individual patient over a predetermined time period that has been 
demonstrated in the target population to have a significant treatment benefit.”14  There 
are currently two broadly accepted methods for determining the MCID: anchor-based 
methods, and distribution based methods, however these is no consensus for preferred 
or stronger method.15–17  Instead, experts agree that a combination of methods may 
provide the best estimation of MCID for a questionnaire or scale. 
 
Current state of the dry eye PROM literature 
 The MCID is established in order to assess a questionnaires’ responsiveness.  
Although responsiveness is included in the COSMIN checklist as important criteria for 
questionnaire validity, it is often left out of validation studies, particularly within the field 
of ophthalmology.18  Two review papers were recently published evaluating existing 
questionnaires used in ophthalmology.  In a review by Khadka and colleagues, the 
authors appraised all existing ophthalmology PRO questionnaires for their psychometric 
properties and validity, including responsiveness.18  However, the authors only included 
three dry eye questionnaires: the Ocular Surface Disease Index (OSID), the Ocular 
Comfort Index (OCI), and McMonnies questionnaire.   
In another review by Guillemin and colleagues, the authors aimed to appraise all 
dry eye PRO instruments for use in clinical trials and also included responsiveness in 
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their appraisal.  Out of 18 identified dry eye questionnaires, the authors reported 
responsiveness assessments for only 5 of the questionnaires.  Neither of the articles 
reports the methods for how the MCID was established for each questionnaire, nor do 
they attempt to evaluate the soundness of the methods.  Another paper published this 
year by my colleagues at UNC reviewing the quality of life measures in dry eye 
questionnaires identified only two questionnaires (OSDI & IDEEL) suited to measure 
QOL.  However, the authors chose not to focus on evaluating the methods used in the 
questionnaires responsiveness or establishing an MCID.19   
 Therefore, no comprehensive systematic review of the methods used for 
determining the MCID or responsiveness in ophthalmology questionnaires currently 
exists.  While PROMs can be extremely useful for assessing patient symptom burden or 
quality life as it relates to dry eye, if a PROM is unable to detect a change over time, or 
nothing is known about the MCID, then the utility for assessing disease severity in order 
to make clinical or therapeutic adjustments is greatly diminished.  In order to help 
providers understand the utility of the questionnaires they use to manage care for 
patients with dry eye, we need to know which questionnaires have an established MCID 








This review attempts to answers the following questions: 
 
Key Question 1: Which validity and reliability studies for questionnaires used in the 
evaluation of symptoms or health-related quality of life in patients with dry eye disease 
have established a minimal clinically important difference (MCID)? 
 
Key Question 2: Which methods are most commonly reported to determine the MCID?   
 




Because responsiveness, which includes establishing an MCID, should be 
established during development or validation of a questionnaire, the eligibility criteria 
were developed to capture any literature involving the development of patient-reported 
questionnaires or their validation.  Studies that independently determine the MCID of an 
existing questionnaire were also intended for capture.  To be included for review, studies 
must have focused on either questionnaire development, assessment of psychometric 
properties, and/or questionnaire validity/reliability.  Articles based on studies of 
questionnaires not related to dry eye, or not based on patient-reported symptoms or 
HRQOL were excluded.  Language or cultural adaptation validation studies for existing 
questionnaires are beyond the scope of reviewing methods for determining 
responsiveness and were also excluded.  Questionnaires meant solely for diagnosis of 
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dry eye disease were also excluded because these questionnaires are not intended for 
repeated use over time in the same patient.  Since the goal of this review is to assess 
the state of the questionnaire validation methods, which should include responsiveness 
but may not, I did not exclude studies based on the methods, quality, or results of the 
studies.   
 
Search Strategy 
I conducted a systematic search of PubMed with a last search date of April 24, 
2014.  With the help of a research librarian, I developed and used the following search 
strategy: “((patient reported[tiab] OR patient-reported[tiab] OR PRO[tiab] OR PROM[tiab] 
OR quality of life[MeSH] OR HRQOL[tiab] OR VRQOL[tiab] OR quality of life[tiab]) AND 
(questionnaires[MeSH] OR questionnaire[tiab] OR scale[tiab] OR instrument[tiab]) AND 
(development[tiab] OR reliability[tiab] OR validity[tiab] OR validation[tiab] OR 
“responsiveness” OR MCID[tiab] OR psychometrics[MeSH]) AND 
(ophthalmology[MeSH] OR ophthalmology[tiab] OR dry eye syndromes[MeSH] OR dry 
eye[tiab] OR ocular surface[tiab]))”.  Search results were restricted by language to 
include only articles published in English.  No other search filters were used.  I also 
conducted individual searches for any validation or MCID literature related to each 
questionnaire include in the DEWS and the paper by Guillemin and colleagues.   
Study selection 
I screened all search results by title and abstract for eligibility and inclusion 
based on the criteria aforementioned and summarized in Table 1.  Any article for which 
sufficient information to determine eligibility was lacking then underwent full-text analysis 
for eligibility.  All articles deemed eligible for inclusion then underwent full-text review.  I 
was the only reviewer.  The study selection process is summarized in Figure 1. 
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Table 1. Modified PICOTS Eligibility Criteria: 
 Inclusion Exclusion 
Population Studies reporting the 
development of questionnaires 
to be used in patients with dry 
eye disease to assess 
symptoms or quality of life 
 
Studies specifically done to 
establish the MCID 
Studies not related to dry eye 
questionnaires 
 
Studies for questionnaires 
meant solely for diagnosis of dry 
eye 
 
Studies of questionnaires not 
based on patient-reported 
symptoms/quality of life 
Intervention Method for determining 
MCID/responsiveness 
 




Time Frame Any  
Study Design Questionnaire validation 
studies; methodological studies 
Non-validation or non-
methodological studies; 
validation studies for language 




To collect data, I developed a data extraction sheet to gather the following 
information from each article: intended purpose for questionnaire development and use, 
responsiveness/MCID statistics, and responsiveness/MCID methods. 
Data Synthesis and Method of Analysis 
Studies were examined for information about questionnaires and their 
development, including the intended use of the questionnaires and the target population.  
All studies were also examined for reporting of psychometric or validity analysis and 
validity and reliability statistics were recorded when reported.  I then assessed whether 
the study attempted to establish the MCID and what methods were used to do so.  Data 
were recorded and organized by either ‘anchor-based methods’ or ‘distribution-based 
methods’ and then I evaluated the methods used.  If the study did not mention of the 
MCID or responsiveness, the lack of data was also recorded in the data extraction sheet.  
- A8 
Figure 1. PRIMSA 2009 Flow Diagram for Study Selection  
Records identified through PubMed  
Limits: English-language articles 
only 



























Additional records identified 
through other sources 
(n =  19) 
Records after duplicates removed 
(n =  82) 
Records screened  
(n = 82) 
Records excluded 
(n =  56) 
Full-text articles assessed 
for eligibility 
(n =  26) 
Full-text articles excluded: 
questionnaires for 
epidemiological studies 
(n = 4) 
Studies included in 
qualitative synthesis 
(n = 22) 
Studies included in 
quantitative synthesis  
(n = 22) 
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RESULTS 
 Literature search yielded 26 articles for full-text review for 21 different dry eye 
questionnaires.  Of those 21 questionnaires, 4 were excluded because their intended 
use was for epidemiological studies (CANDEES, DEEP, Schein, and Women’s Health 
Study) and not for clinical purposes.6,20–23  Of the remaining 17 questionnaires, only the 
CLDEQ-8, DEQ, DEQS, IDEEL, and OSDI reported using the questionnaire to detect 
changes over time with just 3 of those reporting an actual estimation for a minimal 
clinically important difference – the DEQ, OSDI, and the IDEEL.24–29  A list of the 17 
questionnaires and their reasons for development are summarized in Table 3.  The 
instruments that reported any data related to assessing change of symptoms over time 
are summarized in Table 4, with MCID included when reported. 
 
CLDEQ-8 
 The CLDEQ-8 does not have an established or reported MCID.  However, they 
did use the scale to assess symptom changes over a 2-week period in patients 
randomized to two different contact lenses.  They were asked to report their overall 
perceptions of their current contact lenses, and those responses were used as anchors 
for grouping in ANOVA analysis.  The authors considered a change in assessment by 
two steps to be “much worse” or “much better” depending on the associated direction of 
score change.  They found that patients reporting a worse overall opinion (n=73) had a 
8.5 +/-5.8 point increase, those unchanged (n=218) had a -2.3 +/-5.0 decrease, and 
those improved (n=11) had a -16.7 +/-10.0 decrease in score.  The ANOVA determined 
that the distribution was significantly related to change in overall opinion (F=16.5, 
p<0.001).  Again, the authors’ findings may be important, but we are uncertain based on 
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Table 3.  Instruments used for assessing symptoms, health-related quality of life (HRQOL), and/or visual functioning in patients with 
dry eye disease (DED) (n=17) 
 
Acronym Instrument Name Reason for Development 
CLDEQ30 Contact Lens Dry Eye Questionnaire Examine distribution of symptoms (intensity & frequency) among contact 
lenses wearers 
CLDEQ-831 Contact Lens Dry Eye Questionnaire-8 Shorter 8-item version of CLDEQ 
DEQ25 Dry Eye Questionnaire Distinguish diagnosis of DED with Sjogren’s Syndrome (SS) & without 
SS 
DEQ-532 24 Dry Eye Questionnaire-5 Shorter 5-tiem version of DEQ 
DEQS33 Dry Eye Questionnaire Assess symptom severity and effect on HRQOL 
IDEEL28,29 Impact of Dry Eye in Everyday Life Assess symptoms and HRQOL in three domains: HRQOL, treatment 
satisfaction, symptom bother 
McMonnies34 McMonnies Dry Eye Questionnaire Diagnose DED and assess risk factors for developing DED 
NEI-
VFQ2535–37 
National Eye Institute Visual Function 
Questionnaire-25 
Assess influence of vision on multiple dimensions of HRQOL 
OCI38 Ocular Comfort Index Assess severity of discomfort from DED for use in clinical trials 
OSD39 Ocular Surface Disease Assess symptoms, perception of treatment, and HRQOL 
OSDI26,27 Ocular Surface Disease Index Assess symptom severity and their effect on HRQOL in three domains: 
ocular symptoms, vision-related function, and environmental triggers 
SANDE40 Symptom Assessment iN Dry Eye Assess frequency and severity of symptoms 
SSI41 Sicca Symptom Inventory  Assess severity of fatigue and general discomfort in Primary SS 
SIDEQ42 Single Item Score Dry Eye 
Questionnaire 
Assess ocular discomfort due to symptoms 
SPEED43 Standard Patient Evaluation of Eye 
Dryness Questionnaire 
Assess symptoms including diurnal and longer-term symptom changes 
TERTC-
DEQ44 
Texas Eye Research and Technology 
Center Dry Eye Questionnaire 
Assess symptoms, effects of symptoms on patients’ occupation, and 
indicate specific sources of dry eye 
n/a45,46,47 11-question Dry Eye Syndrome 
Questionnaire 
Assess nature, severity and functional impact of symptoms to determine 




Tabel 4. Summary of instruments reporting MCID methods  







Anchor-based: within patient 
global transition assessment 
 
“Which statement best describes 
your overall opinion of your 
current contact lenses: poor, fair 
good, very good, or excellent” 
309 patients randomized to 
two different soft contact 
lenses (senofilcon A or 
lotrafilcon B silicone hydrogel)  
2 weeks ANOVA (p<0.05) 
DEQ >1 unit  Anchor-based: within patient 
global transition  
48 normal and 162 DED 
patients; no data on 
intervention  





Distribution-based? 10 patients who underwent 
punctual plug insertion 






ES = 1.14 
Anchor-based: within patient 
global transition assessment 
 
5-point Likert scale from “much 
worse” to “much better” 
75 non-contact lens wearers 









OSDI 7.0 to 9.9 
overall; 






Anchor-based: within patient 
global transition assessment 
(SGA) and clinician global 
impression (CGI) 
 
Distribution-based: 0.5 SD, effect-
size, standardized response mean 
 
 
310 consecutive patients with 
“suppressed tear production” 

















their methods how meaningful these reported changes are.  Another limitation is the 
large number of patients who reported no change, leaving much smaller sample sizes 
for those reporting improvement of worsening in their opinions, particularly for 
improvement.  Furthermore, these global transition assessments only referred the their 
overall opinion of contact lens use, and not an impression of dry eye symptoms or their 
effects on quality of life. 
 
DEQ 
 I was only able to find limited information on the development of the DEQ.  The 
authors of a paper determining the repeatability of symptoms as captured by the DEQ 
reported finding that a >1 unit change in score should represent a “clinically significant 
treatment effect for use in clinical trials.”25 This reported MCID was determined by 
comparing Kappa values for those reporting no change in symptoms to those who 
reported change as a measure of “responsiveness.”  They found the PM intensity 
questions to be the most responsive with Kappa values for those reporting no change 
ranging from .361 (PM Tired Eyes) to .472 (PM Blurry Vision) compared to .133 (PM 
Dryness) to .181 (PM Tired Eyes) among patients reporting a change (p<0.05).  Again, 
using changes in Kappa scores related to patient-reported global change is not 
commonly cited as a method of determining clinically meaningful changes using patient-
reported questionnaires leaving readers with uncertainty of the true meaning of such a 
change in score. 
 
DEQS 
 The DEQS is a recently developed questionnaire that is meant to address the 
effects of symptoms on HRQOL.  The developers report the motivation for creating this 
questionnaire was to provide an instrument that can be easily used in routine clinical 
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practice and that also covers some of the shortcomings some have reported in the 
OSDI’s ability to cover all relevant domains of DED (Citations, Khadka and DEQS).  As 
part of the development, the authors assessed the following psychometric properties: 
internal consistency, reproducibility, discriminant validity, concurrent validity, and 
responsiveness.  Although they acknowledge the importance of assessing the 
responsiveness of the instrument, they did not report or attempt to establish the MCID.  
Rather, they used within patient global assessment of change before and after punctual 
plug insertion and used paired t-tests to determine statistical significance to the 
differences in scores.   
For changes in DEQS scores before and after punctual plug insertion the authors 
report statistically significant changes in all three subscales: impact on daily life (37.2 to 
20.7; p = 0.04), bothersome ocular symptoms (49.6 to 19.3; p <0.001), and summary 
score (42.1 to 20.0; p = 0.001).  The authors also report statistically significant 
improvements in fluorescein staining and tear film breakup time.  Although the 
improvements in score and clinical findings appear to represent modest improvements, 
the improvements in score are accompanied by large standard deviations due to small 
sample size of just 10 patients.  The paired t-test still showed a statistically significant 
difference, however we are still left with the uncertainty of the meaningfulness of these 
improvements without having a patient-reported global transition assessment.   
 
IDEEL-SB 
 The developers of the IDEEL and IDEEL-SB MCID used the suggested methods 
for determining a MCID.  Using an anchor-based method for assessing patient global 
transitions, they report that a change in score by 12 points reflects a clinically meaningful 
improvement in patient-reported symptoms.  In determining this MCID, rather than take 
an arbitrary average of the scores within each category of reported symptom change, 
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they used ROC analysis to determine the optimal MCID.  They also justified their 
determination of a 12-point cutoff for MCID by comparing it to a 10% change in score 
(10-point difference) and the related effect sizes.  They found that going from 10 to 12 
points improved Kappa scores only marginally, but increased the effect size (EF) by 20% 
and thus chose the 12-point cutoff as the MCID.  One consideration to make when 
evaluating their MCID is that they found no difference between scores at 1 week and at 
4 weeks and decided to combine the data for the analysis.  They also decided to 
collapse the data from 5 categories down to 3 by combining the “much” and “somewhat” 
categories due to low responses in some categories.  As a result, the authors then 
provide the MCID under the assumption that 12-point improvement in score are equally 
meaningful anywhere along the scale’s severity spectrum and does not differentiate 
between different severities.   
 
OSDI 
 The OSDI had the most transparent reporting of methods for a study specifically 
for determining the MCID.  Patients must have had a diagnosis of DED, currently use 
artificial tears daily, normally eyelid position and closure, and also must have been likely 
to complete all required follow-up visits.  Patients were excluded if they used 
cyclosporine ophthalmic emulsion currently or in the past as well as any oral or topical 
ophthalmic cyclosporine use within the past 3 yrs.  Additionally, if patients had a 
condition that was considered to potentially influence a physician’s opinion in a way that 
resulted in risk for the patient or confounded the results, they were also excluded.   
 The authors used an anchor-based within patient global transition assessment 
(SGA) as well clinical global impressions (CGI) to establish and MCID.  They also used 
distribution-based methods to verify their results.  To accommodate for anticipated small 
numbers within the categories for worsening, the authors folded the data to then assess 
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the magnitude in score changes regardless of direction of change.  They found their 
reported MCIDs to be corroborated by the 0.5-SD approach yielding an MCID of 9.8 with 
an effect size of 0.51 and standardized response mean of 0.57.  However, because they 
decided to fold the data, the assumption for the MCID is that the change in score 
representing a worsening of patient-reported symptoms is equivalent to the change in 
score for an improvement.  No explicit follow-up time was required, however the authors 
reported the mean follow-up time in days with the standard deviation for the overall 
group as well as by DED severity.  Follow-up times were significantly longer than the 
other studies ranging from 295.4 days for SGA for patients with moderate DED up to 
464.4 days for CGI for patients with normal eyes. 
  
DISCUSSION AND COMPARISON OF QUESTIONNAIRES  
 Managing chronic disease such as dry eye disease using PRO measures and 
instruments requires that the PRO tool be capable of effectively detecting changes over 
time.  Despite the importance of the responsiveness of a PRO instrument in such 
context, very few questionnaires developed for DED have had their responsiveness 
assessed and/or determined an MCID.  Of those that have reported data for using a 
questionnaire to detect changes over time, even fewer have established an MCID 
according to accepted practices – the OSDI and IDEEL.   
 The CLDEQ-8 developers report that a statistically significant difference in scores 
could be detected based on patient global assessments after a 2-week period.  Although 
the authors’ findings may be important, we are uncertain based on their methods how 
meaningful these reported changes are based on statistical significance alone.  Another 
limitation is the large number of patients who reported no change, leaving much smaller 
sample sizes for those reporting improvement of worsening in their opinions, particularly 
for improvement.  Furthermore, these global transition assessments only referred the 
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their overall opinion of contact lens use, and not an impression of dry eye symptoms or 
their effects on quality of life. 
Authors of the DEQ make the assertion based on their findings that a >1-point 
change would be a clinically important change in score that could be used in clinical 
trials.  However, their assertion is based on a statistically significant difference in Kappa 
scores in those reporting a change in symptoms over time.  Unfortunately, using 
changes in Kappa scores related to patient-reported global change is not commonly 
cited as a method of determining clinically meaningful changes using patient-reported 
questionnaires leaving readers with uncertainty of the true meaning of such a change in 
score. 
The DEQS was developed to be an improvement based on shortcomings 
identified with the OSDI.  The authors recognized the importance of being able to use 
the DEQS to detect treatment effects over time and included an assessment of 
responsiveness.  Although the changes in score and clinical findings appear to represent 
modest improvements, the improvements in score are accompanied by large standard 
deviations due to small sample size of just 10 patients.  The paired t-test still showed a 
statistically significant difference, however we are still left with the uncertainty of the 
meaningfulness of these improvements without having a patient-reported global 
transition assessment to serve as an anchor.  Additionally, we are not provided with any 
information about the 10 patients included in the study and the lack of a control group 
also limits the certainty of the findings.   
 The authors who established the MCID of the IDEEL-SB used methods 
consistent with the accepted literature for determining an MCID of a patient-reported 
questionnaire.  Using ROC analysis to determine the most appropriate cutoff for MCID 
and using multiple methods to support their results contributes to the strength of the 
study.  However, one consideration to make when evaluating their MCID is that they 
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found no difference between scores at 1 week and at 4 weeks and decided to combine 
the data for the analysis.  They also decided to collapse the data from 5 categories down 
to 3 by combining the “much” and “somewhat” categories due to low responses in some 
categories.  As a result, the authors then provide the MCID under the assumption that 
12-point improvement in score are equally meaningful anywhere along the scale’s 
severity spectrum and does not differentiate between different severities.  Lastly, the 
MCID has only been established for the Symptom Bother (SB) module.  However, the 
authors do report use of the IDEEL-SB as a stand alone domain is still shown to be valid 
and reliable. 
 Determination of the MCID of the OSDI was conducted through multiple methods 
including anchor-based methods as well as distribution-based methods to corroborate 
their findings.  This combination has been stated as possibly the most ideal method for 
establishing a meaningful MCID.17  However, there are some limitations in the authors’ 
reports.  Because they decided to fold the data in anticipation of low sample sizes for the 
worsening categories, the assumption for the MCID is that a meaningful change in score 
is independent of the direction of change.  In other words, one’s score would have to 
change by the same amount to represent a meaningful improvement/worsening 
regardless of the direction of the change, which may or may not be accurate.  
Establishing an MCID for each disease severity category, which appears to be an 
important distinction, strengthens their conclusions.  
 
CLOSING COMMENTS 
 The DEWS asserts that “clinically meaningful changes in questionnaire scores 
need to be defined.”48  However, after assessing the state of the literature of patient-
reported instruments in dry eye disease, we find that very few have taken the steps 
towards defining such a change.  Because DED management relies so heavily on 
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patient-reported symptoms, there is an enormous need for valid, reliable, and responsive 
PROMs.  Unfortunately at this time, only 2 questionnaires have made a concerted effort 
to establish an MCID.  Continued work needs to be done to establish the MCID for 
questionnaires that claim to be useful in the clinical setting.  Without an MCID, many 
clinicians are left with little certainty with how to interpret changes in scores over time.  
Until these measures have been determined, their utility in the clinical setting as well as 
research is greatly limited. 
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APPENDIX B: Methods and Questionnaires 
Dry Eye Symptom Change Interviewing Summary 
After I had received IRB approval, I along with another medical student searched 
Dr. Davis’ UNC ophthalmology clinic schedules for patients with dry eye disease who 
had at least one prior DEMS score.   We recruited patients during their regularly 
scheduled appointment while they waited to be seen by their ophthalmologist.  After 
consenting to participate, the patients were asked about their symptoms using the Dry 
Eye Symptom Change Questionnaire (DESCQ).  We administered the questionnaire by 
reading the questions on the DESCQ to the patient and we recorded their answers on 
the questionnaire.  If needed, patients were shown the DESCQ or UNC DEMS for further 
clarification of the questions.  The interviews lasted approximately 5 minutes on average.  
Afterwards, patients underwent usual clinical assessment of dry eye disease, which 
included Schirmer test, Oxford grading scheme, and tear break-up time. 
 
 B2 
Dry Eye Symptom Change Questionnaire 
 
 
First, we’d like to know about your dry eye symptoms.  Please answer the following 
questions: 
 
On the UNC DEMS you filled out today, you chose a score of: ______ 
 
 

































2. If your dry eye symptoms have changed, why do you think they have changed?  










Now, these last questions are about the UNC DEMS questionnaire you’ve filled out. 
 
 
On the UNC DEMS, you choose a number that shows what your symptoms are like.  We 
are trying to understand how well that number can show a change in your symptoms. 
   
 
4. How many points would your score have to change to show that you felt like your 
symptoms were getting better?  That is, how much change would be a meaningful 
improvement in quality of life for you? ______ 
 
(please turn page over)  
 
5. And how many points would your score have to change to show that you felt like your 
symptoms were getting worse?  That is, how much change would mean that your 





6. Last question!  If you could choose a number on the UNC DEMS that would be your 
goal score for treatment of your dry eyes – the place you’d like to get to – what would 




Thank you for your time!  Your responses are very valuable and we appreciate your 
taking the time to fill this out! 
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The UNC Dry Eye Management Scale 
 
